Clopidogrel Tablet, Film Coated
Product Images NDC 50090-5868

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 50090-5868). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Clopidogrel Fig1)

Figure 1 shows the effects on the exposure to the active metabolite of Clopidogrel (a medication used to prevent blood clots) when co-administered with different Proton Pump Inhibitors (PPIs) at various doses. The figure displays the mean and 90% confidence interval for the effect of each PPI on the area under the curve (AUC) of the active metabolite. The PPIs included in the study are Dexlansoprazole, Lansoprazole, Pantoprazole, and Omeprazole, at doses of 60 mg, 30 mg, 80 mg, and 80 mg respectively. The figure also illustrates the change in exposure relative to when Clopidogrel Bisulfate 75 mg is administered alone.*

FDA Label Image

Figure 2: Cardiovascular Death, Myocardial Infarction, And Stroke In The Cure Study (Clopidogrel Fig2)

The given text appears to be a table showing the cumulative event rate for cardiovascular death, myocardial infarction, and stroke for two treatments (Plagebo + aspirin and Clopidogrel Bisulfate + aspirin) over a span of 12 months of follow-up. The table includes the percentage value of the cumulative event rate (%), along with the number of events (N) in each treatment group. Additionally, there is a significance value (P=0.00009) provided at the end of the text.*

FDA Label Image

Figure-3 (Clopidogrel Fig3)

FDA Label Image

Figure 4: Cumulative Event Rates For Death In The Commit Study (Clopidogrel Fig4)

This text appears to be a summary of a study evaluating the effects of a treatment (possibly Clopidogrel) on mortality rates. The text mentions the number of deaths in a placebo group (1845, 8.1%) and a Clopidogrel group (1726, 7.5%). It also states a 7% proportional risk reduction (p = 0.03) associated with the treatment. The text also includes a graph with days since randomization on the x-axis, but the details are not readable. Overall, the text suggests that the treatment may have a positive impact on reducing mortality rates.*

FDA Label Image

Figure 5: Cumulative Event Rates For The Combined Endpoint Re-infarction, Stroke Or Death In The Commit Study (Clopidogrel Fig5)

This text appears to be a comparison between two treatments, "Placeb" and "Clopidogrel", in terms of their effectiveness in reducing certain events (possibly related to health or medical conditions) over a period of 28 days. The text includes percentages and mentions events such as death, re-infarction, and stroke. The data suggests that Clopidogrel may have a lower risk of these events compared to Placeb.*

FDA Label Image

Figure 6: Effects Of Adding Clopidogrel Bisulfate To Aspirin On The Combined Primary Endpoint Across Baseline And Concomitant Medication Subgroups For The Commit Study (Clopidogrel Fig6)

FDA Label Image

Figure 7: Fatal Or Non-fatal Vascular Events In The Caprie Study (Clopidogrel Fig7)

FDA Label Image

Figure 8: Hazard Ratio And 95% Ci By Baseline Subgroups In The Caprie Study (Clopidogrel Fig8)

FDA Label Image

Chemical Structure (Clopidogrel Str)

FDA Label Image

Label Image (Lbl500905868)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.